NEW YORK, June 2, 2016 /PRNewswire/ -- OTC Markets Group Inc. (OTCQX: OTCM), operator of financial markets for 10,000 U.S. and global
securities, today announced NeuroVive
Pharmaceutical AB (STO: NVP; OTCQX: NEVPF), a leading mitochondrial medicine company, located in Lund, Sweden, has qualified to trade on the OTCQX® Best Market. NeuroVive Pharmaceutical AB upgraded to
OTCQX from the Pink® market.
NeuroVive Pharmaceutical AB begins trading today on OTCQX under the symbol "NEVPF." U.S. investors can find current financial
disclosure and Real-Time Level 2 quotes for the company on www.otcmarkets.com.
"We are proud to welcome NeuroVive Pharmaceutical to our family of established, investor-focused U.S. and global companies on
OTCQX," said Jason Paltrowitz, Executive Vice President of Corporate Services at OTC Markets Group. "Upgrading will
allow NeuroVive to expand its shareholder base and visibility in the U.S. market without incurring the high cost and duplicative
regulatory requirements of a U.S. stock exchange listing."
"I am pleased that NeuroVive Pharmaceutical now is trading on the OTCQX Market. The upgrade to OTCQX will increase NeuroVive's
visibility among U.S. investors and potential partners in the U.S. market which is important for us," said NeuroVive´s CEO
Erik Kinnman. "We have seen an increasing interest in the company from U.S. based entities during
recent years and I believe our trading on the OTCQX Market will help us to ensure a strong US presence going forward."
Sanders Ortoli Vaughn-Flam Rosenstadt LLP serves as NeuroVive Pharmaceutical AB's OTCQX Advisor, responsible for providing
professional guidance on OTCQX requirements.
NeuroVive Pharmaceutical AB, is a leading mitochondrial medicine company, located in Lund,
Sweden. The company's focus is on producing drug candidates that protect the integrity of the mitochondria, and enhance
their function in indications with pressing medical need. Research and development is conducted both in-house and in
collaboration with leading international partners. Two of NeuroVive's drug candidates - CicloMulsion® and NeuroSTAT® are
currently in early phase II trials. CicloMulsion® is being studied for preoperative treatment of acute kidney injury (AKI)
coincident with major surgery, and NeuroSTAT® is being studied for treating traumatic brain injury (TBI). NVP019 is also being
developed for the potential use in AKI. In addition to the two clinical trials, NeuroVive also possesses two development
platforms designed to develop drug candidates for treating ischemic stroke and a range of mitochondrial disorders (especially
those that involve dysfunction of mitochondrial respiratory Complex I). NeuroVive was founded by research physicians with the
ambition of transforming research results into new treatments in therapeutic areas with unmet medical needs, including serious
diseases that could lead to organ damage and unusual diseases where current therapy options are extremely limited.
About OTC Markets Group Inc.
OTC Markets Group Inc. (OTCQX: OTCM) operates the OTCQX® Best Market, the OTCQB® Venture
Market, and the Pink® Open Market for 10,000 U.S. and global securities. Through OTC Link® ATS, we connect a diverse network
of broker-dealers that provide liquidity and execution services. We enable investors to easily trade through the broker of
their choice and empower companies to improve the quality of information available for investors.
To learn more about how we create better informed and more efficient markets, visit www.otcmarkets.com
OTC Link ATS is operated by OTC Link LLC, member FINRA/SIPC and SEC regulated ATS.
Subscribe to the OTC Markets RSS Feed
Media Contact:
OTC Markets Group Inc., +1 (212) 896-4428, media@otcmarkets.com
Logo - http://photos.prnewswire.com/prnh/20110118/MM31963LOGO
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/otc-markets-group-welcomes-neurovive-pharmaceutical-ab-to-otcqx-300278396.html
SOURCE OTC Markets Group Inc.